HDL cholesterol reduction during rosiglitazone and fenofibrate treatment in a type 2 diabetes mellitus patient with dyslipidemia

Korean Journal of Laboratory Medicine

Volumn 30, Issue 1, 2010, Pages 17-19

  Im, Mijeong ^a   Kim, Minki ^a   Lee, Jin Kyung ^a   Chang, Yoon Hwan ^a   Lee, Dong Young ^a   Hong, Seok Il ^a   Lee, Yun Yong ^a   Hong, Young Jun ^a  

^a Korea Cancer Center Hospital   (South Korea)

Author keywords

Fenofibrate; HDL cholesterol; Rosiglitazone

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTILIPEMIC AGENT; APOLIPOPROTEIN A1; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ROSIGLITAZONE;

ARTICLE; BLOOD; CASE REPORT; DYSLIPIDEMIA; HUMAN; MALE; METABOLISM; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS;

APOLIPOPROTEIN A-I; CHOLESTEROL, HDL; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; FENOFIBRATE; HUMANS; HYPOLIPIDEMIC AGENTS; MALE; MIDDLE AGED; THIAZOLIDINEDIONES;

EID: 77954859879     PISSN: 15986535     EISSN: None     Source Type: Journal    
DOI: 10.3343/kjlm.2010.30.1.17     Document Type: Article

References (14)

1. Lebovitz HE, Dole JF, Patwardhan R, Rappaport EB, Freed MI. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 2001;86:280-8.
2. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998;98:2088-93.
3. Normén L, Frohlich J, Montaner J, Harris M, Elliott T, Bondy G. Combination therapy with fenofibrate and rosiglitazone paradoxically lowers serum HDL cholesterol. Diabetes Care 2004;27:2241-2.
4. World Health Organization. WHO drug information. Geneva: World Health Organization 2005;19:208.
5. Capps NE. Lipid profiles on fibric-acid derivatives. Lancet 1994;344:684-5.
6. Chandler HA and Batchelor AJ. Ciprofibrate and lipid profile. Lancet 1994;344:128-9.
7. Shetty C, Balasubramani M, Capps N, Milles J, Ramachandran S. Paradoxical HDL-C reduction during rosiglitazone and fibrate treatment. Diabet Med 2007;24:94-7.
8. Sarker A, Semple RK, Dinneen SF, O'Rahilly S, Martin SC. Severe hypo-alpha-lipoproteinemia during treatment with rosiglitazone. Diabetes Care 2004;27:2577-80.
9. Senba H, Kawano M, Kawakami M. Severe decrease in serum HDL-cholesterol during combination therapy of bezafibrate and pioglitazone. J Atheroscler Thromb. 2006;13:263-4.
10. Collinson PO, Hjelm CJ, Canepo-Anson R. Paradoxical high-density lipoprotein reduction induced by fenofibrate and ciprofibrate. Ann Clin Biochem 1996;33:159-61.
11. Beghin L, Capps N, Duhal N, Davies J, Staels B, Luc G. Metabolism of apolipoproteins AI and AII in a patient with paradoxical reduction in high-density lipoprotein due to ciprofibrate. Ann Clin Biochem 1999;36:523-5.
12. Ebcioglu Z, Morgan J, Carey C, Capuzzi D. Paradoxical lowering of high-density lipoprotein cholesterol level in 2 patients receiving fenofibrate and a thiazolidinedione. Ann Intern Med 2003;139:80.
13. Vu-Dac N, Chopin-Delannoy S, Gervois P, Bonnelye E, Martin G, Fruchart JC, et al. The nuclear receptors peroxisome proliferatoractivated receptor alpha and Rev-erbalpha mediate the species-specific regulation of apolipoprotein A-I expression by fibrates. J Biol Chem 1998;273:25713-20.
14. Keidar S, Guttmann H, Stam T, Fishman I, Shapira C. High incidence of reduced plasma HDL cholesterol in diabetic patients treated with rosiglitazone and fibrate. Pharmacoepidemiol Drug Saf 2007;16:1192-4.